Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Posted on another message board....
DoublingDollars
$OPK I heard that Frost hired this guy
"Michael Flaherty is a senior vice president at Gladstone Place Partners, where has advised companies on shareholder activism defense and preparation, M&A, corporate governance communications, CEO transitions and reputation management."
gladstoneplace.com/team/mic...
NOTICE OF
SPECIAL MEETING
TO BE HELD ON DECEMBER 28, 2020
TO THE STOCKHOLDERS OF RMG ACQUISITION CORP.:
NOTICE IS HEREBY GIVEN that a special meeting of RMG Acquisition Corp. (“RMG”), a Delaware corporation, will be held at 10:00 a.m. eastern time, on December 28, 2020, in a virtual format. You are cordially invited to attend the special meeting, which will be held for the following purposes:
(1)
Proposal No. 1 - The Business Combination Proposal—to consider and vote upon a proposal to approve and adopt the Agreement and Plan of Merger, dated as of October 5, 2020, as amended by Amendment No. 1 to Agreement and Plan of Merger dated as of November 18, 2020 (the “Merger Agreement”), by and among RMG, RMG Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of RMG (“Merger Sub”), and Romeo Systems, Inc., a Delaware corporation (“Romeo”), a copy of which is attached to this proxy statement/consent solicitation statement/prospectus as Annex A, and the transactions contemplated thereby, including the merger of Merger Sub with and into Romeo, with Romeo surviving as a wholly owned subsidiary of RMG (the “Business Combination”)—we refer to this proposal as the “business combination proposal”;
(2)
Proposal No. 2 - The RMG Charter Proposals—to consider and vote upon separate proposals to approve amendments to RMG’s current amended and restated certificate of incorporation to: (i) change the name of the public entity to “Romeo Power, Inc.” as opposed to “RMG Acquisition Corp.”; (ii) increase RMG’s capitalization so that it will have 250,000,000 authorized shares of a single class of common stock and 10,000,000 authorized shares of preferred stock, as opposed to RMG having 100,000,000 authorized shares of Class A common stock, 10,000,000 authorized shares of Class B common stock and 1,000,000 authorized shares of preferred stock; and (iii) delete the various provisions applicable only to special purpose acquisition corporations (such as the obligation to dissolve and liquidate if a business combination is not consummated within a certain period of time)—we refer to these proposals collectively as the “RMG charter proposals”;
(3)
Proposal No. 3 - The NYSE Proposal—to consider and vote upon a proposal to approve, for purposes of complying with applicable listing rules of The New York Stock Exchange (the “NYSE”), the issuance of shares of Class A common stock pursuant to the Business Combination and the issuance of shares of Class A common stock to certain accredited investors or qualified institutional buyers in a private placement, the proceeds of which will be used to finance the Business Combination and related transactions and the costs and expenses incurred in connection therewith with any balance used for working capital purposes—we refer to this proposal as the “NYSE proposal”;
(4)
Proposal No. 4 - The Director Election Proposal—to approve of the appointment of nine directors who, upon consummation of the Business Combination, will become the directors of the Combined Company—we refer to this proposal as the “director election proposal”;
(5)
Proposal No. 5 - The Incentive Plan Proposal—to consider and vote upon a proposal to approve the 2020 Long-Term Incentive Plan, which is an incentive compensation plan for employees of the Combined Company and its subsidiaries, including Romeo and its subsidiaries—we refer to this proposal as the “incentive plan proposal”;
(6)
Proposal No. 6 - The Adjournment Proposal—to consider and vote upon a proposal to adjourn the special meeting to a later date or dates if it is determined that more time is necessary or appropriate, in the judgment of RMG’s board of directors or the officer presiding over the special meeting, for RMG to consummate the Business Combination (including to solicit additional votes in favor of any of the foregoing proposals)—we refer to this proposal as the “adjournment proposal.”
These items of business are described in the attached proxy statement/consent solicitation statement/prospectus. We encourage you to read the attached proxy statement/consent solicitation statement/prospectus in its entirety, including the Annexes and accompanying financial statements, before voting. IN PARTICULAR, WE URGE YOU TO CAREFULLY READ THE SECTION ENTITLED “RISK FACTORS.”
XSPA not servicing this site!
Passengers taking off from Fort Lauderdale-Hollywood International Airport can check off one more thing on their travel list: Have an optional COVID-19 test on the go.
Beginning Wednesday, for a fee, passengers can choose to take a test — whether it’s because their destination wants proof they aren’t sick, or as a last-minute assurance to protect grandma back home.
Two tests will be available: One that offers quick results, and one that takes longer but is considered to be the most accurate.
The Fort Lauderdale airport will be the latest U.S. airport to start offering COVID-19 tests. About half of the country’s 30 large hub airports already offer them.
One of the other South Florida airports also may soon offer the tests, too: Palm Beach International Airport isn’t providing them, but a provider could be chosen in February, according to a spokeswoman.
Testing at the Fort Lauderdale airport will be available from 7 a.m. to 9 p.m. seven days a week at the Terminal 3 baggage claim pre-security area — near JetBlue and Spirit Airlines, which makes up 93% of the international flights, said Mark Gale, director of aviation for Fort Lauderdale-Hollywood International Airport.
RELATED: Tourism stocks rally on news of possible COVID-19 vaccine »
The plan is the brainchild of County Commissioner Mark Bogen, who was inspired by Tampa International Airport, which was the first U.S. airport to make both types of COVID-19 tests available to all ticketed passengers in October.
“By offering it at the airport, it might help increase passenger traffic to those destinations who require a COVID test when you arrive, which might help air traffic,” Bogen said. “It will allow passengers to reach more destinations that require test results.”
Gale said the demand is there.
Masked passengers check into a Spirit Airlines flight, Wednesday. Dec. 2, 2020, at Fort Lauderdale Hollywood Ineterantional Airport. The airport will begin offering onsite 15 minute COVID-19 rapid tests.
Masked passengers check into a Spirit Airlines flight, Wednesday. Dec. 2, 2020, at Fort Lauderdale Hollywood Ineterantional Airport. The airport will begin offering onsite 15 minute COVID-19 rapid tests. (Joe Cavaretta / South Florida Sun Sentinel)
The state of Pennsylvania, for example, required travelers to show a negative test to enter just before Thanksgiving, he said. “This is an amenity that is in demand by our patrons, [as a] destination-specific requirement as well as the opportunity to take a test prior to going home and visiting family and loved ones.”
Gale said he hoped the availability of the tests would “boost confidence in flying.”
He expects “several hundred tests a day” — not to the general public, but only those with a ticket or travel itinerary through Fort Lauderdale.
The agency conducting the testing will be Utah-based Nomi Health, which launched in 2019 to provide services by eliminating traditional corporate health insurance plans.
RELATED: Travelers slow to venture out despite excitement about COVID-19 vaccine »
Viola Hysenlika, a spokeswoman for BayCare Health System, which administers the tests in Tampa, said the response there has been successful.
From Oct. 1 through Nov. 30, there have been 3,984 PCR nasal swab tests that get results in about 48 hours, and can be reserved by passengers who have a plane flight three days later. There have been 3,659 rapid antigen tests, also nasal swabs, that have results within 15 minutes, she said.
Breaking News Alerts Newsletter
As it happens
Get updates on the coronavirus pandemic and other news as it happens with our free breaking news email alerts.
Fort Lauderdale will offer the same two tests.
RELATED: These South Florida hospitals will be among the first with the COVID-19 vaccine »
The list is constantly changing, but just a few of the places that currently require visitors to have negative test results include the Bahamas, Barbados and Belize. The state of Hawaii also requires proof its tourists don’t have the virus.
Some facts about the testing:
Passengers can register online, choose walk-up testing if there is available space, and get test results emailed.
The cost to take the PCR COVID-19 test will be $99 and the rapid antigen test will be $69.
The Miami International Airport will not offer testing.
The airport instead decided to “encourage travelers to get tested before arriving at MIA, to avoid the inconvenience of rescheduling or canceling their travel plans at the airport if they receive a positive test result,” said Greg Chin, agency spokesman. “We also want to avoid passengers testing positive at the airport and potentially trying to move forward with their travel plans anyway.”
In Broward, Gale said if someone tests positive, that information could be shared with the airline, preventing the passenger from flying.
OPKO gets NBA contract
Article posted on another board.
Sure would be nice if our wonderful IR firm issued a PR....
A cautious start to NBA season, as camps open amid positives
By TIM REYNOLDS
Updated: December 1, 2020 - 8:05 PM
The first day of NBA training camp is supposed to be accompanied by brimming optimism, a time for players and coaches all taking those first steps toward what they hope is a championship.
It was tempered this year.
The first preseason camps of the coronavirus era opened Tuesday, with teams limited for the first few days to individual sessions with one coach and one player at one basket, all of this starting to happen as the pandemic continues raging and more and more Americans are testing positive — including at least three NBA players in recent days.
Content Continues Below
“I’m very concerned if we can pull this off,” Philadelphia coach Doc Rivers said.
He probably isn’t alone.
Golden State general manager Bob Myers said two Warriors have tested positive, meaning that club won't start individual workouts until Wednesday and won't have a full-scale practice until Monday. Washington coach Scott Brooks said the Wizards have one player who tested positive. And Orlando coach Steve Clifford said Magic center Mo Bamba — who tested positive several months ago — is still “a ways away” from being ready to play again.
“I don't think this is unexpected," Myers said. “Kind of proves that the protocols and testing are working. ... That's all per NBA protocols, which I'm learning a lot about."
Rivers, noting how the virus is becoming a major issue for college football and the NFL in terms of getting games played, said the effect on an NBA team losing a key player or two for even a short period could essentially wreck a season.
“In football they play once a week and they have 1,000 players, so when you miss three or four players, you can still get away with it,” Rivers said. “If we miss three or four players, we’re in trouble, especially with the amount of games. We’re playing three and four games a week. So, if one of our guys or two of our key guys get the virus and they miss 10 days, 14 days, that can be eight games in a 72-game season. That can knock you out in the playoffs.”
The Wizards didn’t say what player tested positive, though Brooks said the player has yet to be around the team in Washington and that “everybody else is ready to go.” The Warriors also didn't reveal who had positive tests, citing league rules and privacy policies. Bamba was diagnosed with COVID-19 on June 11, played sparingly in Orlando’s first two games at Walt Disney World during the NBA’s restart there this summer, then sat out the rest of the season for additional testing.
“Right now, we’re hoping that he can get healthy enough to get back on the floor,” Clifford said. “He’s going to be able to do some of the things early in camp, but he’s going to be limited. He’s had kind of a tough stretch here in terms of how much he’s been able to do. We have to be prudent and make sure we’re moving along with him in an intelligent manner.”
Players and coaches are being tested daily and that is likely to be the plan for throughout the season. Protocols that the league sent to teams late last week suggested that, in many cases, it would take at least 12 days for a player to be able to return to play after testing positive for the coronavirus.
The league had no positive tests once players entered the restart bubble over the summer. But now back in the real world, with travel and hotels and airplanes back in the mix, San Antonio coach Gregg Popovich said the challenge will fall on individuals to do the right things.
“Here, people are coming in and out, it'll be much more difficult and the discipline will have to be even greater," Popovich said. “But I think the understanding is, to make it work, we have an even greater responsibility than we had in Orlando. The league made it easy for us in Orlando, in my opinion, and as we all know did a great job. But here, a lot more of the onus is on individuals and teams."
The NBA is working with BioReference — a company that also handled testing in the bubble, at the league’s expense of about $140 per test — for standardized league-wide testing, and that company will likely have personnel traveling with teams this season to handle testing on the road. The league has said that its testing program does not impact BioReference’s nationwide testing capabilities or use public health resources in a time where more and more Americans are seeking testing.
“I’m pretty comfortable with it,” Boston coach Brad Stevens said. “As we saw with the bubble, the NBA crosses every ‘t’ and dots every ‘i.’ They have been great communicating with all of us ... and I’m looking forward to hopefully getting together and starting practice soon as a group.”
Some teams will be able to start those group practices — and 5-on-5 sessions — Friday. Most other NBA clubs will be able to start Sunday. Injuries will be a worry, as will conditioning, but the daily testing numbers seem like they'll overshadow everything.
“As a coach, you want to go in with your team concerns being more basketball,” Rivers said. “And I think every coaches’ concerns right now are probably non-basketball.”
___
More AP NBA: https://apnews.com/NBA and https://twitter.com/AP_Sports
I disagree with you.
I suggest that anything positive is relative and should be PR'd to the public. It won't hurt to see that additional sources of revenue are being generated. There have been multiple contracts this past year about testing that has not been PR'd..I find that dumb.
Rite Aid announced this morning opening 1,000 new sites
BRL will do the testing. Did anyone see a PR from OPK?
No, Neither did I.
It's a small wonder that Sian is unhappy.
November 24, 2020 11:04 AM Eastern Standard Time
CAMP HILL, Pa.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions.
The updated release reads:
RITE AID UPDATES COVID-19 TESTING PROGRAM
Asymptomatic testing will be available for individuals 13 and older at existing Rite Aid testing sites
To continue to provide its customers with an essential service during the pandemic, Rite Aid (NYSE: RAD) is updating its COVID-19 testing program through its partnership with the U.S. Department of Health and Human Services (HHS). Effective immediately, no-charge testing at Rite Aid’s existing testing sites will be expanded to individuals 13 years of age and older – regardless of whether the individual is symptomatic or asymptomatic.
Rite Aid’s COVID-19 testing locations utilize simple self-swab nasal tests overseen by Rite Aid pharmacists, and operate Monday through Friday 10 a.m. - 8 p.m. and Saturday and Sunday 10 a.m. - 5 p.m. At all testing locations, adult patients will be required to provide government issued identification and need to pre-register online at www.riteaid.com in order to schedule a time slot for testing. Testing will be temporarily unavailable at Rite Aid sites on Thanksgiving and Friday, November 27. Testing will resume on Saturday, November 28.
Previously, testing was only available to individuals 18 years of age or older. The expanded program allows parents or legal guardians of individuals 13-18 years of age to create Baseline COVID-19 accounts so that they may be screened and tested. Parents or legal guardians must provide consent for individuals under 18, show their government issued identification and must accompany their children to the appointment and supervise them during the test.
“We’re proud to continue serving as an essential part of the pandemic response in the neighborhoods we serve,” said Heyward Donigan, president and chief executive officer, Rite Aid. “Continuing to make testing available – and now, to a broader age range – is an important next step in continuing to fight COVID-19.”
Currently operating 301 testing sites across 15 states, Rite Aid has been on the front lines of the COVID-19 pandemic, partnering with Verily and its Baseline COVID-19 Testing Program to provide screening, scheduling and return of results to participants for Rite Aid testing sites. BioReference Laboratories provides COVID-19 laboratory testing, while clinical oversight is provided by PWNHealth, a national clinician network that enables safe and easy access to diagnostic testing.
Rite Aid will continue to provide regular updates on the company's progress with COVID-19 testing. A complete list of Rite Aid’s COVID-19 testing sites can be found at www.riteaid.com.
About Rite Aid Corporation
Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to more than 1.6 million Americans daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 18 states. Through Elixir, we provide pharmacy benefits and services to approximately 4 million members nationwide. For more information, www.riteaid.com.
Contacts
MEDIA:
Chris Savarese
717-975-5718
christopher.savarese@riteaid.com
Trying to post the links again...
OPKO Governance Matters | November 12, 2020
White Paper 1: Principles of Corporate Governance | November 12, 2020
White Paper 2: Fundamental Value Addendum | November 12, 2020
White Paper 3: Macro Commentary on Week of November 3, 2020 | November 12, 2020
Dont forget to read the white papers too
OPKO Governance Matters | November 12, 2020
White Paper 1: Principles of Corporate Governance | November 12, 2020
White Paper 2: Fundamental Value Addendum | November 12, 2020
White Paper 3: Macro Commentary on Week of November 3, 2020 | November 12, 2020
Yes they are...
Thanks for calling me out on that!
Thanks....
Much appreciated.
Wish I recognized some of those names, but as long as they keep increasing their purchases, who cares?
Thanks for the inf.
GLTA
Thanks for referring me to that filing.
That was the filing I was referring to and read it again.
Still cant find the answers to those questions I posed earlier.
I see that their business is mainly in PRC and Asia, but no mention of who the top five companies that account for the majority of their business which is down year over year.
I noticed that there is one majority owner and a lot of loans.
If you could direct me to what page in that filing mentions those companies doing business with WETH, I would be very appreciative.
TIA
Trying to figure out this company
Just noticed in my account shares of WETH.
After reading this board I realize shares of GLFWD are now WETH. Completely forgot that company was in my account as the symbol was not apparent for years. (TD changed it to numbers and I just disregarded)
So I see the new company makes touch screens for various products.
Can anyone tell me who the clients are? What are the prospects for the future? Do they manufacture anything else?
Any info would be appreciated.. I read the SEC filing for the reverse merger but cant find any news or info. Even went to the website, but nothing pertinent, IMO>
Thanks in advance...
Could anyone tell me what GLFWD did.. Completely forgot all about them. I think they changed symbols multi times thru the years!!!
New form 4s out.
Our wonderful management team is raping the company and stealing from us.
Way to go!!
Thanks for your response.
You think its dead money too?
Midastouch, Where are you?
Really enjoyed all your research and comments.
Are you just lurking or out?
Hope all is well.
TFMG--Thanks for the chart...But
Would you be kind enough to explain what you are seeing?
TIA
PP.. Thanks for your reply
In the interim, I went to the website and looked at the October presentation.
They think DEA approval will come in 4th qtr, (which is now) and Launch will take place in 1Q 21.
It was originally approved Aug 7, so I am guessing with 90 days from that. Just a guess.
Any idea when we can expect the US DEA to assign it to its
schedule of controlled substances?
Do they assign it a date like FDA does with PDUFA?
Took this paragraph from their press release..
OLINVYK is a new chemical entity approved by the FDA in August 2020. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK will not be available for distribution until the United States Drug Enforcement Administration assigns it to its schedule of controlled substances. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.
New MTA contract
https://new.mta.info/document/21261
Borrowed from Yahoo
Colleagues,
Your hard work and dedication to keeping the New York region moving throughout this pandemic have been unmatched. We want to assure you that our top priority continues to be your health and safety.
That’s why the MTA is announcing a new voluntary, on-site COVID-19 Screening Program at no cost to employees. As part of MTA’s COVID response protocols and as health experts continue to warn of a second wave, this new on-site screening effort will serve as an additional precautionary measure designed to monitor the health of essential employees, help stop the spread of the virus and maintain a safe work environment.
The initial phase of the new program will launch on Monday, October 26th and include a three-pronged testing approach:
1. Field Sites: On-site testing will be made available on a rotating schedule at select employee facilities. These locations will be determined by MTA Occupational Health Services (OHS) in coordination with operating agencies, prioritizing the hotspot and cluster zone changes made by New York State.
2. Medical Assessment Centers (MACs) and Occupational Health Services (OHS) Facilities: Testing will also be offered to all employees scheduled to visit a MAC or OHS facility. Employees must register to come into a MAC or OHS facility if you are not already scheduled to visit.
3. Existing Partnership with Northwell Health: Additionally, free diagnostic testing remains available to MTA workers at Northwell Health-GoHealth Urgent Care centers throughout the New York metropolitan region.
The COVID-19 Screening Program will be expanded to additional sites and scaled up in the coming weeks. Check back here to get an updated schedule of screening locations.
Here’s how the new screening program works: The MTA is partnering with BioReference Laboratories to perform testing. Testing will be conducted as a PCR nasal swab—which is considered the most accurate test available—and will take approximately five minutes. The program is voluntary, but participation is strongly recommended. Turnaround time for results will be 24-48 hours under normal circumstances and employees will receive their results in that timeframe.
The initial sites we plan to roll out in the next two weeks are as follows:
• Flatbush Bus Depot
• East New York Bus Depot
• Ulmer Park Bus Depot
• Jackie Gleason Bus Depot
• Grand Avenue Bus Depot
• College Point Bus Depot
• Jamaica Bus Depot
• JFK Bus Depot
• Queens Village Bus Depot
• Gun Hill Bus Depot
• West Farms Bus Depot
• Charleston Bus Depot
• Medical Assessment Center 1
• Medical Assessment Center 3
• Medical Assessment Center 5
• OHS Graybar Facility (MNR)
• OHS Mineola Facility (LIRR)
• 207th Street Yard
• Coney Island Yard
• Hillside Yard (LIRR)
Reminder: If you are sick, stay home.
The new screening program is targeted at identifying asymptomatic carriers. We continue to have incidents where employees are reporting to work at MTA locations with COVID-19 like symptoms, including high fever and loss of smell and taste. The implications of coming to work while experiencing symptoms are very serious and puts others at risk and violates our healthcare protocols.
Additionally, we encourage you to get your free flu shot this year which you can get at more than 50 select MTA locations and at all MTA MACs, at your own physician, or free of charge at all Walgreens locations in the New York metropolitan area with a voucher.
Please visit the MTA COVID-19 Employee Resources page to learn more information and sign up today, call the COVID-19 Hotline at 646-252-2010, or speak directly with your manager.
Additionally, testing information can also be found at the New York State Department of Health, or by calling the NYS COVID-19 Hotline at 1-888-364-3065.
Together we can work to keep each other safe during this unprecedented public health crisis.
Regards,
Patrick Warren
Chief Safety Officer
BB... What about reaching out to the Senate
Lamar Alexander heads up the Health, Education committee.
Maybe he would be interested in hearing.
Just a thought.
Chattanooga Office
Joel E. Soloman Federal Building
900 Georgia Avenue, #260
Chattanooga, TN 37402
Address: 455 Dirksen Office Building, Washington, DC 20510 | Phone: (202) 224-4944 | Fax: (202) 228-3398
STS
Get some Voltaren Gel and apply 3-4 times a day.
you will see a big difference after a week.
My podiatrist recommended it after I tore some tendons in my heel. Used to be by prescription but
now available OTC at all the drug stores, Walmart Costco, etc.
I even use it on my arthritic knee..
Thanks DG
Can you post the link for the full interview.
TIA
three out of five sold.
In my opinion, whether they bought and held or
bought and sold is irrelevant. Options should be
a reward for a job well done.
The only thing that is almost done is our company,
on their watch.
Options should have and could have been suspended, especially for
our fearless leader who was one of those selling.
A bunch of 4k's just dropped
Management has no shame whatsoever.
They sure take care of themselves.
WOW!
I hope you sent it certified with a return receipt request.
Thanks for your hard work...
Thank you Canes
Has this 3 Judge Panel also ruled on the first case they heard yesterday?
What did they decide there?
DG... I think you are wrong.
If Cohen had something to hide he would not make an appearance.
I believe it gives him an opportunity to explain what the problem was and how it was fixed.
Remember the PR said there was a slight contamination, Not an error in the testing.
Hoping we get clarity.
Thanks for all the info you post.
Question... How long does it take to get a peer review completed and published?
TIA
Press Release: XpresSpa Group Provides Business Update and Announces Second Quarter 2020 Financial Results
4:45 pm ET August 19, 2020 (Dow Jones)
XpresSpa Group Provides Business Update and Announces Second Quarter 2020 Financial Results
Views Addressable Market for XpresCheck(TM) of 60 U.S. Airports in Addition to International Opportunities
Preparing to Implement Rapid COVID-19 Testing and Begin Expanding into Additional Health and Wellness Services
Files SEC Form 10-Q for the Second Quarter ending June 30, 2020
Conference Call and Webcast Scheduled for 5:00 PM ET Today
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA), a health and wellness company, today provided a business update and announced that it has filed financial results on SEC Form 10-Q for the second quarter ending June 30, 2020.
Doug Satzman, XpresSpa Group CEO, stated, "Our vision for XpresCheck is taking shape and we see a significant opportunity to expand the concept across the country as we capitalize on the societal changes coming to U.S. airports as a result of COVID-19. We are now operating XpresCheck in both JFK and Newark and are in active discussions with other airports for further development. We are also lobbying our elected officials and consulting with related government agencies to support COVID-19 testing specifically at U.S. airports as part of the next stimulus bill."
Mr. Satzman added, "While providing COVID-19 testing is a critical starting point for XpresCheck, and we are committed to offering the latest and best testing available on the market, we believe the possibilities for advancing health and wellness care within airports is much greater. In the near-term, we are looking to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu. We also see ourselves as well positioned to be part of the national rollout of a COVID-19 vaccination when it becomes available. However, our overarching and longer-term goal will be for XpresCheck to expand into health and wellness services and amplify care for airport employees and the traveling public as they pass through the largest U.S. airports."
Business Update
XpresSpa Traditional Services
On March 24, 2020, XpresSpa temporarily closed all of its global spa locations. This was largely due to the categorization of such spa locations by local jurisdictions as "non-essential services" in connection with COVID-19. The Company had hoped to see some signs of a recovery in airport traffic as early as May and continuing through the balance of the quarter and beyond; however the increase in infections in most states coupled with mandated 14-day quarantines for incoming travelers across many states has resulted in minimal air travel to date. This in turn resulted in fewer passengers in the terminals.
The Company did not reopen any domestic spa locations during the second quarter 2020 for traditional spa services nor does it anticipate reopening any domestic spas in the third quarter 2020 for traditional spa services. The Company did reopen its XpresSpa spas in Dubai International Airport, UAE on July 7, 2020 for select spa services. However, the performance over the last several weeks has been muted given limited airport traffic.
XpresCheck Opportunity
During the first quarter 2020, the Company announced that it was in advanced conversations with certain COVID-19 testing partners to develop a model for testing in U.S. airports. The Company subsequently launched the XpresCheck brand under its newly formed XpresTest, Inc. subsidiary.
The Company believes that similar to how the 9/11 terrorist attacks forever changed security protocol in travel, COVID-19 will have a similar impact on health and security protocols in travel, and that given its lease portfolio the Company is well-positioned to help assist on this societal change.
There are approximately 30 major U.S. airports with an average of 30,000 employees who support airport activity ("Large Hubs") airports. There are also another 30 secondary U.S. airports with an average of 15,000 employees who support airport activity ("Medium Hubs") airports. The Company considers these 60 U.S. airports as initial priority, in addition to various international locations, as it develops the XpresCheck concept. The Company currently has XpresSpa facilities in 19 of the Tier One airports and 4 of the Tier Two airports.
The Company is in active discussions with multiple U.S. airports (primarily Large Hubs) to open new testing centers or convert existing XpresSpa spas to XpresCheck. However, the timing of these possible openings has not been finalized.
Importantly, the Company is beginning its XpresCheck concept rollout and expansion of services by addressing the urgent needs caused by the COVID-19 pandemic that adds risk and uncertainty related to domestic and international air travel as well as to our front line airport workforce while intending to build out more comprehensive health and wellness service capabilities over time.
-- For example, XpresCheck is in the planning stages to expand testing to
other communicable diseases as well as administer vaccinations such as
flu shots.
-- The Company further views itself as well-positioned to be part of the
national rollout of a COVID-19 vaccination when it becomes available in
the market.
On June 22, 2020, the Company opened XpresCheck at JFK International Airport in the Arrivals Hall of Terminal 4.
-- The modular constructed testing facility hosts nine separate testing
rooms with a capacity to administer over 500 COVID-19 tests per day.
-- COVID-19 testing was initially offered to airline employees, contractors
and workers, airport concessionaires and their employees, TSA officers,
and U.S. Customs and Border Protection agents, but was expanded to the
traveling public effective August 10, 2020. Patients can either register
for an appointment at XpresCheck.com or stop by for a walk-in. We are
targeting our public testing to help passengers meet testing requirements
in select states and countries.
On August 17, 2020, the Company opened its second XpresCheck testing facility, located at Newark Liberty International Airport in Terminal B.
-- The modular constructed facility hosts six separate testing rooms with a
capacity to administer over 350 tests per day.
-- Similar to JFK, initial testing is limited to airline employees and
related parties, but over time will expand to the public as well.
COVID-19 Testing and Expansion of Medical Services
The Company is currently using polymerase chain reaction (PCR) testing, also known as a nasal swab test, and blood antibody testing, which looks for markers in the blood (IgG, IgM) that suggests a person might have had COVID-19. These tests are sent to outside laboratories. All insurance plans are accepted and all information remains private and HIPAA compliant.
-- The Company is committed to reviewing and pursuing the latest COVID-19
testing technology and offering the best available testing on the market
including FDA-approved quick testing, as well as new, emerging testing
protocols that may provide high accuracy, simplicity and speed, such as
antigen testing.
-- The Company is in on-going conversations with multiple quick testing
companies that would complement the airport environment. The Company
plans to deploy these emerging technologies to current and future
XpresCheck sites as soon as reasonably possible although we cannot assure
you whether this will occur in the near term or at all.
-- The Company is actively lobbying elected officials and consulting with
government agencies as its advocates specifically for COVID-19 testing
funding at U.S. airports as part of the next stimulus bill.
Liquidity and Financial Condition
As of June 30, 2020, XpresSpa Group had cash and cash equivalents, excluding restricted cash, of $37.8 million, total current assets of $39.0 million, total current liabilities of $19.6 million, and positive working capital of $25.8 million (which includes a $6.4 million non-cash derivative liability) compared to a working capital deficiency of $12.3 million as of December 31, 2019.
During the quarter ended June 30, 2020, to address XpresSpa Group's historical working capital deficiencies, and outstanding long-term debt, the Company raised net proceeds of approximately $38.4 million, net of approximately $4.7 million in offering expenses, in a series of registered direct equity offerings, which eliminated the working capital deficiency and resulted in the positive working capital position as of June 30, 2020.
During the second quarter, XpresSpa Group settled its long-term debt owed as of March 31, 2020 by converting $5.7 million of its senior secured note due in May 2021 to Common Stock and by converting its $2.5 million unsecured note due in May 2022 to Common Stock. The Company also paid in full its short-term $0.9 million advance funding, realizing a discount in the principal repayment amount of approximately $91,000. Finally, on May 1, 2020, the Company entered into a U.S. Small Business Administration ("SBA") Paycheck Protection Program ("PPP") promissory note in the principal amount of $5.7 million.
As of June 30, 2020, the Company has approximately 56.5 million shares of common stock outstanding (adjusted to reflect the impact of the 1:3 reverse stock split that became effective on June 11, 2020) and warrants to purchase up to an aggregate of 8.5 million shares of common stock that are immediately exercisable at an average price of approximately $5.38 per share.
Summary of Second Quarter 2020 Financial Results
(MORE TO FOLLOW) Dow Jones Newswires
August 19, 2020 16:45 ET (20:45 GMT)
Send Management an email expressing your indignation.
I did earlier. Not that anything will come of it.
Get In Touch With Us
Address
955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087
Phone Tel: (610) 354-8840
Email: ir@trevena.com
CEO featured on Fast Money
$WKHS youtube.com/watch?v=FeYRbUO...
Workhorse CEO Duane Hughes on Lordstown Motors public debut
Duane Hughes, Workhorse CEO, on Lordstown Motors going public and the surge in EV stocks. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim ...
YouTube
Rite Aid Expands COVID-19 Testing to 258 Total Locations
9:30 am ET July 15, 2020 (BusinessWire) Print
Rite Aid (NYSE: RAD) will continue to expand its COVID-19 testing capacity with the addition of 161 drive-through testing locations opening on July 16 in partnership with the U.S. Department of Health and Human Services (HHS).
Rite Aid's COVID-19 testing sites will now span coast-to-coast, with the addition of locations in California, Oregon and Washington, and an increased number of locations in Idaho, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania and Virginia.
Similar to Rite Aid's existing drive-through locations, the new sites will utilize self-swab nasal tests overseen by Rite Aid pharmacists, and will operate Monday through Friday 10 a.m. - 8 p.m. and Saturday and Sunday 10 a.m. - 5 p.m.
Rite Aid's COVID-19 nasal tests are available for all adults, regardless if they are experiencing virus symptoms, in accordance with the Centers for Disease Control and Prevention (CDC) guidance. At all testing locations, patients are required to provide government issued identification, be at least 18 years old and need to pre-register online at www.riteaid.com in order to schedule a time slot for testing.
Now operating 258 total testing sites, Rite Aid will more than double its testing capabilities, with the capacity to conduct 94,000 tests weekly across all locations. A complete list of Rite Aid's COVID-19 testing sites can be found at www.riteaid.com.
Rite Aid partners with Verily and its Baseline COVID-19 Testing Program to provide screening, scheduling and return of results to participants for Rite Aid testing sites. BioReference Laboratories provides COVID-19 laboratory testing.
Clinical oversight for the COVID-19 testing program is provided by PWNHealth, a national clinician network that enables safe and easy access to diagnostic testing.
Rite Aid will continue to provide regular updates on the company's progress with COVID-19 testing.
About Rite Aid Corporation
Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to more than 1.6 million Americans daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 18 states. Through EnvisionRxOptions, we provide pharmacy benefits and services to approximately 4 million members nationwide. For more information, www.riteaid.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200715005504/en/
SOURCE: Rite Aid Corporation
MEDIA:
Chris Savarese
717-975-5718
christopher.savarese@riteaid.com
Bio Reference now being used by NBA also.
https://www.nbcsports.com/philadelphia/nba-insider-tom-haberstroh/covid-testing-priority-potential-issue-nba
What is the award date of the USPS contract?
Can anyone confirm that July 14th is the award date or is that the
RFP date?
Thanks
Hearing BITG Raises Workhorse Price Target From $6 To $10, Saying It Believes Co. Looks To Be On The Cusp Of Department Of Transportation Approvals For Series C; Unconfirmed
4:24 pm ET June 18, 2020 (Benzinga) Print
Latest Ratings for WKHS DateFirmActionFromTo
Apr 2020Roth CapitalInitiates Coverage OnBuy Jan 2020BTIGInitiates Coverage OnBuy Jul 2018Cowen & Co.MaintainsOutperformOutperform
View More Analyst Ratings for WKHS
View the Latest Analyst Ratings
$5.56 in after hours at 6:21 PM
Rite Aid expands partnership with Bio Reference
Rite Aid expands COVID-19 sample collection sites
Jun. 10, 2020 10:01 AM ET|About: Rite Aid Corporation (RAD)|By: Douglas W. House, SA News Editor
Rite Aid (RAD +1.7%) announces 21 new drive-through locations effective tomorrow, June 11, through its partnership with the U.S. Department of Health and Human Services (HHS).
Locations now total 92 and have the capacity to collect almost 47K swab specimens for COVID-19 testing each week. OPKO's BioReference Lab unit is performing the actual diagnostic work.
Bio Ref partners with MLS in Orlando
https://www.mlssoccer.com/mls-is-back-tournament/health-and-safety-protocols
Somatrogon Phase 3 Pediatric Trial Results will be presented on June 8 at ENDO Online 2020
April 22, 2020
MIAMI, April 22, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today provided an update on two abstracts regarding the global Phase 3 somatrogon pediatric trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency (GHD). The data from the two abstracts, which were previously accepted for oral presentation at the Endocrine Society’s (ENDO) 2020 meeting, will now be combined into a single presentation at ENDO Online 2020, a virtual event being held June 8 through 22 that will feature on-demand and live programming. The virtual event will incorporate select content from the ENDO 2020 meeting previously scheduled for March 29 through 30 in San Francisco, which was cancelled due to the COVID-19 outbreak.
The results of the pivotal Phase 3 study will be delivered on June 8, 2020 at 11:00 a.m. Eastern time by Dr. Cheri Deal, the Principal Investigator of the Pediatric study. The presentation will be available to those registered for ENDO Online 2020.
The two abstracts entitled “Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Phase 3” and “Interpretation of Insulin-like Growth Factor (IGF-1) Levels Following Administration of Somatrogon (a long-acting Growth Hormone-hGH-CTP)” will be published online in the April-May supplemental issue of the Journal of Endocrinology Society.
On October 21, 2019, OPKO Health and Pfizer Inc. announced that the global Phase 3 trial met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months.
In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. Under the agreement, OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, as well as statements about expected benefits of hGH-CTP. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
https://www.opko.com/investors/news-events/press-releases/detail/386/somatrogon-phase-3-pediatric-trial-results-will-be
opko.jpg
Is This AERG'S????
https://www.kcra.com/article/us-navy-laser-weapon-destroy-aircraft-mid-flight/32654329
A U.S. Navy warship has successfully tested a new high-energy laser weapon that can destroy aircraft mid-flight, the Navy's Pacific Fleet said in a statement Friday.
Images and videos provided by the Navy show the amphibious transport dock ship USS Portland executing "the first system-level implementation of a high-energy class solid-state laser" to disable an aerial drone aircraft, the statement said.
The images show the laser emanating from the deck of the warship. Short video clips show what appears to be the drone burning.
The Navy did not give a specific location of the laser weapons system demonstrator (LWSD) test, saying only that it occurred in the Pacific on May 16.
The power of the weapon was not disclosed, but a 2018 report from the International Institute for Strategic Studies said it was expected to be a 150-kilowatt laser.
"By conducting advanced at sea tests against UAVs and small crafts, we will gain valuable information on the capabilities of the Solid State Laser Weapons System Demonstrator against potential threats," Capt. Karrey Sanders, commanding officer of Portland, said in the statement.
"With this new advanced capability, we are redefining war at sea for the Navy."
The Navy says lasers, which it calls directed energy weapons (DEW), can be effective defenses against drones or armed small boats.
"The Navy's development of DEWs like the LWSD provide immediate warfighter benefits and provide the commander increased decision space and response options," the statement said.
In 2017, the amphibious transport ship USS Ponce performed a live-fire exercise of a 30-kilowatt laser weapon in the Persian Gulf.
At the time, Lt. Cale Hughes, a laser weapons system officer, described how they work.
"It is throwing massive amounts of photons at an incoming object," Hughes said. "We don't worry about wind, we don't worry about range, we don't worry about anything else. We're able to engage the targets at the speed of light."
The Ponce was retired from service later that year.